Posts by: Diogo Pinto

News

Cellectar Biosciences and Orano Med, two companies using distinct strategies to develop innovative therapies for cancer, are joining forces to advance a class of anti-cancer therapies called phospholipid drug ... Read more

August 9, 2018

Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes

News

Poteligeo (mogamulizumab-kpkc) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides and Sézary syndrome — two types of cutaneous T-cell lymphoma — in ... Read more

July 30, 2018July 31, 2018

Revlimid-Rituxan Combo May Replace Chemo, Delay Decline for Some Lymphoma Patients, Phase 3 Trial Shows

News

Adding Revlimid (lenalidomide) to Rituxan (rituximab) in the treatment of follicular lymphoma and marginal zone lymphoma patients who failed at least one prior therapy significantly delays disease progression or death, a Phase ... Read more

May 25, 2018

Revlimid-Rituxan Combo Could Replace Chemo as Follicular Lymphoma Therapy, Phase 3 Trial Suggests

News

A combination of Rituxan (rituximab) and Revlimid (lenalidomide) is similarly effective and has a better safety profile than the standard first-line regimen — chemotherapy and Rituxan — for follicular lymphoma patients, a Phase ... Read more

Posts by: Diogo Pinto

Diogo Pinto

Cellectar and Orano Med Collaborating to Advance Innovative Anti-Cancer Therapy

Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes

Revlimid-Rituxan Combo May Replace Chemo, Delay Decline for Some Lymphoma Patients, Phase 3 Trial Shows

Revlimid-Rituxan Combo Could Replace Chemo as Follicular Lymphoma Therapy, Phase 3 Trial Suggests

Pin It on Pinterest